Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution.

"This move could become … as transformational as few acquisitions have been for the industry," said CEO Albert Bourla.

March 1, 2024 Check out STAT+

Sponsored By

Giannis Papanikos/AP STAT+ | Pfizer is about to make a big push in cancer. Will investors listen? In an interview, CEO Albert Bourla was insistent that investors are missing the potential of Pfizer's acquisition of Seagen. By Matthew Herper Opinion: New federal guidance is hurting cancer patients, especially those in rural areas A new approach to enforcing the Stark Law is wasting cancer drugs and forcing sick patients to make unnecessary trips. By Samyukta Mullangi STAT+ | This chemist's last startup sold for $4 billion. Now investors have poured $173 million into her next act Jean Cui's new company is preparing to start clinical studies of potential medicines that could someday treat blood cancer and lung cancer. By Matthew Herper Boston Globe Photo Import STAT+ | Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships The company is developing cancer treatments using corkscrew-shaped peptides called helicons that could possibly better breach cells. By Allison DeAngelis STAT+ | Here are the cancer drugs Pfizer thinks could reignite investors' interest In describing drugs in its pipeline, Pfizer noted that the mix of small molecule drugs in its cancer portfolio will drop from 94% last year to 35% in 2030. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser